<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01272141</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00031112</org_study_id>
    <secondary_id>WCI1711-09</secondary_id>
    <nct_id>NCT01272141</nct_id>
  </id_info>
  <brief_title>A Study of Lapatinib in Combination With Everolimus in Patients With Advanced, Triple Negative Breast Cancer</brief_title>
  <official_title>Phase II Trial of Lapatinib in Combination With Everolimus in Triple Negative Metastatic or Locally Advanced Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The patient is being asked to join this clinical research study to find out if lapatinib, an
      agent that targets a protein, called epidermal growth factor receptor (EGFR) on the surface
      of cancer cells in combination with everolimus, an agent that targets a protein in the cancer
      cell, called mammalian target of rapamycin (mTOR) is effective in metastatic triple negative
      breast cancers that are no longer controlled by standard chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow accrual, Funding stopped
  </why_stopped>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate Will Measured Using Response Evaluation Criteria in Solid Tumors (RECIST) Criteria. Tumor Assessment for All Lesions Must be Performed Every Eight Weeks While on Study by CT Scan.</measure>
    <time_frame>Tumor assessment for all lesions must be performed by CT scan every 8 weeks while on study.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The Safety and Toxicity of the Combination Therapy of Lapatinib and Everolimus Will be Monitored Using the NCI Common Toxicity Criteria for Adverse Effects (CTCAE) v. 3.0. The Incidence of Any Grade 3 or 4 Toxicities Will be Analyzed.</measure>
    <time_frame>Safety assessments will be performed every four weeks while the patient remains on study.</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Breast Neoplasms</condition>
  <condition>Breast Cancer</condition>
  <condition>Cancer of the Breast</condition>
  <arm_group>
    <arm_group_label>Arm A: Lapatinib plus Everolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lapatinib and Everolimus</intervention_name>
    <description>Lapatinib: 1250 mg by mouth daily
Everolimus: 5mg by mouth daily</description>
    <arm_group_label>Arm A: Lapatinib plus Everolimus</arm_group_label>
    <other_name>Lapatinib</other_name>
    <other_name>Tykerb</other_name>
    <other_name>Everolimus</other_name>
    <other_name>Affinitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed ER(-), PR(-), HER2(-) locally advanced or
             metastatic breast cancer

          -  Disease progression following prior first line cytotoxic chemotherapy in metastatic
             setting

          -  At least 1 lesion measurable by Response Evaluation Criteria in Solid Tumors (RECIST)
             criteria

          -  Age &gt;18 years old

          -  Female

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  Left ventricular ejection fraction (LVEF) &gt; 50%

          -  Absolute neutrophil count (ANC)&gt;1500/mm3; platelets &gt;100,000/mm3; hemoglobin &gt; 9 g/dL;
             serum creatinine &lt; 1.5x upper limit of normal (ULN); total bilirubin &lt; 1.5x ULN,
             aspartate aminotransferase (AST) and alanine aminotransferase (ALT) &lt; 2.5x ULN

          -  Patients must be recovered from both acute and late effects of any prior surgery,
             radiotherapy or other antineoplastic therapy

          -  Patients or their legal representatives must be able to read, understand and provide
             informed consent to participate in the trial.

          -  Patients of childbearing potential agree to use an effective form of contraception
             during the study and for 90 days following the last dose of study medication (an
             effective form of contraception is an oral contraceptive or a double barrier method)

        Exclusion Criteria:

          -  Patients with current active hepatic or biliary disease (except for patients with
             Gilbert's syndrome, asymptomatic gallstones, liver metastases or stable chronic liver
             disease per investigator assessment)

          -  Patients with an active infection or with a fever &gt; 101.3 Fahrenheit within 3 days of
             the first scheduled day of protocol treatment

          -  Patients with active central nervous system (CNS) metastases. Patients with stable CNS
             disease, who have undergone radiotherapy at least 4 weeks prior to the planned first
             protocol treatment and who have been on a stable dose of corticosteroids for 3 weeks
             are eligible for the trial

          -  History of prior malignancy within the past 5 years except for curatively treated
             basal cell carcinoma of the skin or cervical intra-epithelial neoplasia with two
             consecutive normal pap smears 6 months apart

          -  Patients who received radiotherapy to more than 25% of their bone marrow; or patients
             who received radiotherapy to target lesions within 4 weeks of entry

          -  Patients who are receiving concurrent investigational therapy

          -  Peripheral neuropathy &gt;= Grade 2

          -  Patients who are pregnant or lactating

          -  Any other medical condition, including mental illness or substance abuse, deemed by
             the Investigator to be likely to interfere with a patient's ability to sign informed
             consent, cooperate and participate in the study, or interfere with the interpretation
             of the results.

          -  History of allogeneic transplant

          -  Known HIV or Hepatitis B or C (active, previously treated or both)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Read, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University Winship Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Grady Memorial Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory Midtown (Crawford Long Hospital)</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30329</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 6, 2011</study_first_submitted>
  <study_first_submitted_qc>January 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2011</study_first_posted>
  <results_first_submitted>September 3, 2014</results_first_submitted>
  <results_first_submitted_qc>September 3, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 10, 2014</results_first_posted>
  <last_update_submitted>September 11, 2014</last_update_submitted>
  <last_update_submitted_qc>September 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 22, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>William Read</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Metastatic breast cancer</keyword>
  <keyword>Triple negative breast cancer</keyword>
  <keyword>Estrogen receptor (ER)/progesterone receptor (PR)/human epidermal growth factor receptor 2 (HER2)-negative breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lapatinib</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm A: Lapatinib Plus Everolimus</title>
          <description>Lapatinib and Everolimus: Lapatinib: 1250 mg by mouth daily
Everolimus: 5mg by mouth daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm A: Lapatinib Plus Everolimus</title>
          <description>Lapatinib and Everolimus: Lapatinib: 1250 mg by mouth daily
Everolimus: 5mg by mouth daily</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>41-45 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>46-50 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>51-55 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Response Rate Will Measured Using Response Evaluation Criteria in Solid Tumors (RECIST) Criteria. Tumor Assessment for All Lesions Must be Performed Every Eight Weeks While on Study by CT Scan.</title>
        <time_frame>Tumor assessment for all lesions must be performed by CT scan every 8 weeks while on study.</time_frame>
        <population>No data were collected due to early termination.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: Lapatinib Plus Everolimus</title>
            <description>Lapatinib and Everolimus: Lapatinib: 1250 mg by mouth daily
Everolimus: 5mg by mouth daily</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate Will Measured Using Response Evaluation Criteria in Solid Tumors (RECIST) Criteria. Tumor Assessment for All Lesions Must be Performed Every Eight Weeks While on Study by CT Scan.</title>
          <population>No data were collected due to early termination.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Safety and Toxicity of the Combination Therapy of Lapatinib and Everolimus Will be Monitored Using the NCI Common Toxicity Criteria for Adverse Effects (CTCAE) v. 3.0. The Incidence of Any Grade 3 or 4 Toxicities Will be Analyzed.</title>
        <time_frame>Safety assessments will be performed every four weeks while the patient remains on study.</time_frame>
        <population>No data were collected due to early termination.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: Lapatinib Plus Everolimus</title>
            <description>Lapatinib and Everolimus: Lapatinib: 1250 mg by mouth daily
Everolimus: 5mg by mouth daily</description>
          </group>
        </group_list>
        <measure>
          <title>The Safety and Toxicity of the Combination Therapy of Lapatinib and Everolimus Will be Monitored Using the NCI Common Toxicity Criteria for Adverse Effects (CTCAE) v. 3.0. The Incidence of Any Grade 3 or 4 Toxicities Will be Analyzed.</title>
          <population>No data were collected due to early termination.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Arm A: Lapatinib Plus Everolimus</title>
          <description>Lapatinib and Everolimus: Lapatinib: 1250 mg by mouth daily
Everolimus: 5mg by mouth daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Shortness of breath due to pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>William Read, MD</name_or_title>
      <organization>Emory University School of Medicine</organization>
      <phone>1-888-946-7447</phone>
      <email>william.l.read@emory.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

